Stock N1VO34 NOVO NORDISK A/S
Add to a list
To use this feature you must be a member
Log inSign up

News Novo Nordisk A/S Sao Paulo

Equities

N1VO34

BRN1VOBDR005

Market Closed - Sao Paulo
Other stock markets
 21:05:00 12/06/2024 BST 		5-day change 1st Jan Change
97.01 BRL +1.89% Intraday chart for Novo Nordisk A/S +3.65% +55.29%
06-12 Novo Nordisk, Eli Lilly's Weight-Loss Drugs Coverage Dropped by Blue Cross Blue Shield of Michigan MT
06-12 Global markets live: Apple, Oracle, Amazon, Boeing, Tesla... Our Logo

Summary

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Novo Nordisk, Eli Lilly's Weight-Loss Drugs Coverage Dropped by Blue Cross Blue Shield of Michigan
MT
Global markets live: Apple, Oracle, Amazon, Boeing, Tesla...
Our Logo
Health Care Down as Rally Pauses -- Health Care Roundup
DJ
Sector Update: Health Care Stocks Softer Late Afternoon
MT
Novo Nordisk to Face Senate Panel Subpoena Vote Over Ozempic, Wegovy Prices
MT
Sector Update: Health Care Stocks Decline Tuesday Afternoon
MT
Sector Update: Health Care
MT
Surging Biotech M&A Reaffirms Massive Opportunity In Rare Disease Drug Development (CRDL,JAZZ, NVO, AZN, SNY)
AQ
Novo Nordisk President to Face Senate Panel Subpoena Vote Over Ozempic, Wegovy Prices
MT
US Senate Committee to Subpoena Novo Nordisk Inc. President Over Prices of Diabetes, Obesity Drugs
MT
Senate Committee to Vote June 18 to Subpoena Novo Nordisk President Doug Langa
MT
US Senate panel to weigh Novo Nordisk subpoena over Ozempic, Wegovy prices
RE
Surging Biotech M&A Reaffirms Massive Opportunity In Rare Disease Drug Development
AQ
Dsm-firmenich sees boost as weight-loss drugs spur healthier choices
RE
Argus Research Raises Novo Nordisk Price Target to $160 From $125, Maintains Buy Rating
MT
Novo Nordisk A/S - share repurchase programme
GL
Added health benefits of Wegovy, Zepbound could attract more men, doctors say
RE
Novo Nordisk braces for Ozempic rivals in China
RE
European equities gain on tech boost in run-up to ECB
RE
Novo Nordisk Faces Competition in China for Key Ingredient in Diabetes, Weight Loss Drug
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. NOVO B Stock
  4. N1VO34 Stock
  5. News Novo Nordisk A/S
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW